Eradication of Pseudomonas aeruginosa biofilms on cultured airway cells by a fosfomycin/tobramycin antibiotic combination

Pathogens and Disease

Volumn 67, Issue 1, 2013, Pages 39-45

  Anderson, Gregory G ^a   Kenney, Thomas F ^b   Macleod, David L ^b   Henig, Noreen R ^c   O'Toole, George A ^d  

^a INDIANA UNIVERSITY   (United States)

^b GILEAD SCIENCES INC   (United States)

^c GILEAD SCIENCES   (United States)

^d DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Antibiotic resistance; Biofilm; Fosfomycin; Pseudomonas aeruginosa; Tobramycin

Indexed keywords

FOSFOMYCIN; LACTATE DEHYDROGENASE; TOBRAMYCIN;

ARTICLE; BIOFILM; CELL CULTURE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG POTENTIATION; ERADICATION THERAPY; HUMAN; HUMAN CELL; LUNG FIBROSIS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RESPIRATORY EPITHELIUM;

ANTI-BACTERIAL AGENTS; BIOFILMS; CELL SURVIVAL; CELLS, CULTURED; COLONY COUNT, MICROBIAL; DRUG SYNERGISM; EPITHELIAL CELLS; FOSFOMYCIN; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; TOBRAMYCIN;

EID: 84878157909     PISSN: None     EISSN: 2049632X     Source Type: Journal    
DOI: 10.1111/2049-632X.12015     Document Type: Article

References (42)

1. Altes Gutierrez A & Rodriguez Noriega A (1977) In vitro sensitivity of anaerobic bacteria to fosfomycin. Chemotherapy 23(Suppl 1): 51-57.
2. Anderson GG, Moreau-Marquis S, Stanton BA & O'Toole GA (2008) In vitro analysis of tobramycin-treated Pseudomonas aeruginosa biofilms on cystic fibrosis-derived airway epithelial cells. Infect Immun 76: 1423-1433.
3. Anderson GG, Yahr TL, Lovewell RR & O'Toole GA (2010) The Pseudomonas aeruginosa magnesium transporter MgtE inhibits transcription of the type III secretion system. Infect Immun 78: 1239-1249.
4. Borriello G, Werner E, Roe F, Kim AM, Ehrlich GD & Stewart PS (2004) Oxygen limitation contributes to antibiotic tolerance of Pseudomonas aeruginosa in biofilms. Antimicrob Agents Chemother 48: 2659-2664.
5. Boucher RC (2004) New concepts of the pathogenesis of cystic fibrosis lung disease. Eur Respir J 23: 146-158.
6. Bruscia E, Sangiuolo F, Sinibaldi P, Goncz KK, Novelli G & Gruenert DC (2002) Isolation of CF cell lines corrected at DeltaF508-CFTR locus by SFHR-mediated targeting. Gene Ther 9: 683-685.
7. Cozens AL, Yezzi MJ, Chin L, Simon EM, Finkbeiner WE, Wagner JA & Gruenert DC (1994) CFTR expression and chloride secretion in polarized immortal human bronchial epithelial cells. Am J Respir Cell Mol Biol 10: 38-47.
8. Doring G, Parameswaran IG & Murphy TF (2011) Differential adaptation of microbial pathogens to airways of patients with cystic fibrosis and chronic obstructive pulmonary disease. FEMS Microbiol Rev 35: 124-146.
9. Emerson J, McNamara S, Buccat AM, Worrell K & Burns JL (2010) Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008. Pediatr Pulmonol 45: 363-370.
10. Geller DE, Pitlick WH, Nardella PA, Tracewell WG & Ramsey BW (2002) Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 122: 219-226.
11. Gibson RL, Burns JL & Ramsey BW (2003) Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 168: 918-951.
12. Gomez MI & Prince A (2007) Opportunistic infections in lung disease: Pseudomonas infections in cystic fibrosis. Curr Opin Pharmacol 7: 244-251.
13. Goodman AL, Kulasekara B, Rietsch A, Boyd D, Smith RS & Lory S (2004) A signaling network reciprocally regulates genes associated with acute infection and chronic persistence in Pseudomonas aeruginosa. Dev Cell 7: 745-754.
14. Griese M, Kappler M, Gaggar A & Hartl D (2008) Inhibition of airway proteases in cystic fibrosis lung disease. Eur Respir J 32: 783-795.
15. Hammett-S r CA & Johns T (1998) Laboratory guidelines for monitoring of antimicrobial drugs. National Academy of Clinical Biochemistry. Clin Chem 44: 1129-1140.
16. Hauser AR & Engel JN (1999) Pseudomonas aeruginosa induces type-III-secretion-mediated apoptosis of macrophages and epithelial cells. Infect Immun 67: 5530-5537.
17. Inouye S, Watanabe T, Tsuruoka T & Kitasato I (1989) An increase in the antimicrobial activity in vitro of fosfomycin under anaerobic conditions. J Antimicrob Chemother 24: 657-666.
18. Kuchma SL, Connolly JP & O'Toole GA (2005) A three-component regulatory system regulates biofilm maturation and type III secretion in Pseudomonas aeruginosa. J Bacteriol 187: 1441-1454.
19. Kulasekara HD, Ventre I, Kulasekara BR, Lazdunski A, Filloux A & Lory S (2005) A novel two-component system controls the expression of Pseudomonas aeruginosa fimbrial cup genes. Mol Microbiol 55: 368-380.
20. Kumon H, Ono N, Iida M & Nickel JC (1995) Combination effect of fosfomycin and ofloxacin against Pseudomonas aeruginosa growing in a biofilm. Antimicrob Agents Chemother 39: 1038-1044.
21. Laskowski MA, Osborn E & Kazmierczak BI (2004) A novel sensor kinase-response regulator hybrid regulates type III secretion and is required for virulence in Pseudomonas aeruginosa. Mol Microbiol 54: 1090-1103.
22. Lopez-Boado YS & Rubin BK (2008) Macrolides as immunomodulatory medications for the therapy of chronic lung diseases. Curr Opin Pharmacol 8: 286-291.
23. MacLeod DL, Barker LM, Sutherland JL, Moss SC, Gurgel JL, Kenney TF, Burns JL & Baker WR (2009) Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis. J Antimicrob Chemother 64: 829-836.
24. MacLeod DL, Velayudhan J, Kenney TF, Therrien JH, Sutherland JL, Barker LM & Baker WR (2012) Fosfomycin enhances the active transport of tobramycin in Pseudomonas aeruginosa. Antimicrob Agents Chemother 56: 1529-1538.
25. Mah TF & O'Toole GA (2001) Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol 9: 34-39.
26. Monden K, Ando E, Iida M & Kumon H (2002) Role of fosfomycin in a synergistic combination with ofloxacin against Pseudomonas aeruginosa growing in a biofilm. J Infect Chemother 8: 218-226.
27. Moreau-Marquis S, Bomberger JM, Anderson GG, Swiatecka-Urban A, Ye S, O'Toole GA & Stanton BA (2008) The {Delta}F508-CFTR mutation results in increased biofilm formation by Pseudomonas aeruginosa by increasing iron availability. Am J Physiol Lung Cell Mol Physiol 295: L25-L37.
28. Moreau-Marquis S, O'Toole GA & Stanton BA (2009) Tobramycin and FDA-approved iron chelators eliminate Pseudomonas aeruginosa biofilms on cystic fibrosis cells. Am J Respir Cell Mol Biol 41: 305-313.
29. Moreau-Marquis S, Redelman CV, Stanton BA & Anderson GG (2010) Co-culture models of Pseudomonas aeruginosa biofilms grown on live human airway cells. J Vis Exp 44: e2186.
30. Mowat E, Paterson S, Fothergill JL, Wright EA, Ledson MJ, Walshaw MJ, Brockhurst MA & Winstanley C (2011) Pseudomonas aeruginosa population diversity and turnover in cystic fibrosis chronic infections. Am J Respir Crit Care Med 183: 1674-1679.
31. Patel R (2005) Biofilms and antimicrobial resistance. Clin Orthop Relat Res 437: 41-47.
32. Plummer A & Wildman M (2011) Duration of intravenous antibiotic therapy in people with cystic fibrosis. Cochrane Database Syst Rev 1: CD006682.
33. Ratjen F, Brockhaus F & Angyalosi G (2009) Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a review. J Cyst Fibros 8: 361-369.
34. Sato H & Frank DW (2004) ExoU is a potent intracellular phospholipase. Mol Microbiol 53: 1279-1290.
35. Shrestha NK & Tomford JW (2001) Fosfomycin: a review. Infect Dis Clin Pract 10: 255-260.
36. Smith EE, Buckley DG, Wu Z et al. (2006) Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc Natl Acad Sci USA 103: 8487-8492.
37. Stover CK, Pham XQ, Erwin AL et al. (2000) Complete genome sequence of Pseudomonas aeruginosa PA01, an opportunistic pathogen. Nature 406: 959-964.
38. Swiatecka-Urban A, Brown A, Moreau-Marquis S et al. (2005) The short apical membrane half-life of rescued {Delta}F508-cystic fibrosis transmembrane conductance regulator (CFTR) results from accelerated endocytosis of {Delta}F508-CFTR in polarized human airway epithelial cells. J Biol Chem 280: 36762-36772.
39. Walters MC 3rd, Roe F, Bugnicourt A, Franklin MJ & Stewart PS (2003) Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of Pseudomonas aeruginosa biofilms to ciprofloxacin and tobramycin. Antimicrob Agents Chemother 47: 317-323.
40. Wood LF, Leech AJ & Ohman DE (2006) Cell wall-inhibitory antibiotics activate the alginate biosynthesis operon in Pseudomonas aeruginosa: roles of sigma (AlgT) and the AlgW and Prc proteases. Mol Microbiol 62: 412-426.
41. Xu KD, Stewart PS, Xia F, Huang CT & McFeters GA (1998) Spatial physiological heterogeneity in Pseudomonas aeruginosa biofilm is determined by oxygen availability. Appl Environ Microbiol 64: 4035-4039.
42. Yahr TL & Wolfgang MC (2006) Transcriptional regulation of the Pseudomonas aeruginosa type III secretion system. Mol Microbiol 62: 631-640.